Home/Posts/Wataru Akahata

About Wataru Akahata

This author has not yet filled in any details.
So far Wataru Akahata has created 6 blog entries.

VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine


Gaithersburg, MD – VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase I/IIa clinical trial has begun recruiting participants in February 2019, and is designed to assess the safety, immunogenicity and efficacy

VLP Therapeutics Awarded $3.9 million Grant by Global Health Innovative Technology Fund for Further Development of Dengue Vaccine


December 12, 2018 Gaithersburg, MD - The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine. “The GHIT Fund’s commitment is an important step for the further validation of our virus-like particle vaccine technology. We are grateful to the GHIT

Wataru Akahata, Ph.D. Recognized by the Japanese Government as 2018 Significant Researcher


November 29, 2018 Dr. Wataru Akahata, CEO and Founder of VLP Therapeutics was  Selected by the Government of Japan as a 2018 Researcher of Significant Contribution to Science  Japan’s National Institute of Science and Technology Policy (NISTEP) and the Japan Ministry of Education, Culture, Sports, Science and Technology (MEXT) (http://www.nistep.go.jp/en/). An announcement by MEXT in

VLP Therapeutics Announces Issuance of US Patent for Dengue Vaccine


October 18, 2018 Gaithersburg, MD -- VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on which the Company’s dengue vaccine is based and which could form the basis for other flavivirus vaccines. The patent relates

VLP Therapeutics is Recognized by the Government of Japan (Cabinet Office) “Comprehensive Strategy on Science, Technology and Innovation for 2017”


VLP Therapeutics was recently recognized as one of eleven companies that exemplify Japan’s commitment to Innovation as outlined in the 2017 Comprehensive Strategy on Science, Technology and Innovation. In 2017 the Cabinet Office of the Government of Japan published a Comprehensive Strategy on Science, Technology and Innovation which outlined a strategy to enhance Japan’s industrial

VLP Therapeutics announces the Issuance of US Patent #9,969,986


Patent covers a virus-like particle comprising a viral structural protein comprising modified envelope protein E3 Gaithersburg, Md. — May 18, 2018 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and new cancer therapies, announced that the U.S. Patent and Trademark Office has issued US

Go to Top